Amgen reveals new combination data for KRAS inhibitor
Phase Ib CodeBreaK study evaluated Lumakras in over ten different investigational combination regimens
Read More
Tag: KRAS inhibitor
Amgen files KRAS inhibitor sotorasib with EMA
Submission supported by results from phase II CodeBreaK 100 study
Read More
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
